NASDAQ · Biotechnology

Liminal BioSciences Inc. (LMNL) Stock

$8.50 +0.12% NASDAQ: LMNL Healthcare

Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies.

Valuation

MetricValue
Price$8.50
Market Cap$27.62M
P/E Ratio-0.03
P/B Ratio0.03
P/S Ratio96.84
EPS (TTM)$-9.32
52-Week High$8.50
52-Week Low$3.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-73.35%
ROA-57.31%
ROCE-81.71%
Gross Margin100.00%
Operating Margin—
Net Margin—
Debt/Equity0.04
Current Ratio4.09

Annual Financials (USD)

Metric20182019202020212022
Revenue$47.0M$5.0M$3.0M$1.0M$0
Operating Profit$-114.0M$-211.0M$-94.0M$-50.0M$-33.0M
Net Profit$-195.0M$-234.0M$-122.0M$-45.0M$-29.0M
EPS$-2359.49$-145.82$-49.97$-14.94$-9.32
Op Margin-239.7%-4295.1%-2842.1%-7707.1%-8223.2%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$103.0M$165.0M$118.0M$126.0M$50.0M
Total Liabilities$166.0M$70.0M$103.0M$92.0M$14.0M
Cash$7.0M$61.0M$45.0M$108.0M$37.0M
Borrowings$133.0M$47.0M$74.0M$61.0M$1.0M

Latest News

Vallourec to supply pipes for Atapu 2 offshore project in Brazil Offshore Technology · Jul 23, 2026 Micron and Sandisk Are Surging: Can the Rally Last Through 2027? Motley Fool · Jul 23, 2026 1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds StockStory · Jul 23, 2026 CRIF India Launches Chennai Chapter of 'Credit Goes to HER' to Strengthen Women's Leadership in the Credit Ecosystem PR Newswire · Jul 23, 2026 Net Asset Value(s) Business Wire · Jul 23, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-82.0M$-99.0M$-76.0M$-100.0M$-32.0M
Investing Cash Flow$-11.0M$32.0M$0$170.0M$4.0M
Financing Cash Flow$72.0M$118.0M$57.0M$-8.0M$-45.0M
Net Cash Flow$-16.0M$54.0M$-16.0M$63.0M$-71.0M
Free Cash Flow$-88.0M$-104.0M$-78.0M$-100.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.10
FCF Yield-81.99%
Quick Ratio4.09
Interest Coverage-30.59
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Liminal BioSciences Inc.

Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.

Liminal BioSciences Inc. is headquartered in CA.

Liminal BioSciences Inc. (LMNL) stock trades at $8.50 with a market capitalization of $27.62M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of 0.03, price-to-sales of 96.84. Over the past 52 weeks the stock has ranged between $3.10 and $8.50, and currently trades at its 52-week high.

On profitability, Liminal BioSciences Inc. generates a return on equity (ROE) of -73.35%, return on capital employed of -81.71%.

Official website: www.liminalbiosciences.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides